Top

Published in:

01-10-2020 | Neuroendocrine Tumor | Pancreatic Tumors

Specific Growth Rate as a Predictor of Survival in Pancreatic Neuroendocrine Tumors: A Multi-institutional Study from the United States Neuroendocrine Study Group

Authors: Jordan J. Baechle, BS, Paula Marincola Smith, MD, Marcus Tan, MD, Carmen C. Solórzano, MD, Alexandra G. Lopez-Aguiar, MD, Mary Dillhoff, MD, Eliza W. Beal, MD, George Poultsides, MD, Eleftherios Makris, MD, Flavio G. Rocha, MD, Angelena Crown, MD, Clifford Cho, MD, Megan Beems, MD, Emily R. Winslow, MD, Victoria R. Rendell, MD, Bradley A. Krasnick, MD, Ryan Fields, MD, Shishir K. Maithel, MD, Christina E. Bailey, MD, Kamran Idrees, MD

Published in: Annals of Surgical Oncology | Issue 10/2020

Abstract

Background

Pancreatic neuroendocrine tumors (PNETs) are often indolent; however, identifying patients at risk for rapidly progressing variants is critical, particularly for those with small tumors who may be candidates for expectant management. Specific growth rate (SGR) has been predictive of survival in other malignancies but has not been examined in PNETs.

Methods

A retrospective cohort study of adult patients who underwent PNET resection from 2000 to 2016 was performed utilizing the multi-institutional United States Neuroendocrine Study Group database. Patients with ≥ 2 preoperative cross-sectional imaging studies at least 30 days apart were included in our analysis (N = 288). Patients were grouped as “high SGR” or “low SGR.” Demographic and clinical factors were compared between the groups. Kaplan–Meier and log-rank analysis were used for survival analysis. Cox proportional hazard analysis was used to assess the impact of various clinical factors on overall survival (OS).

Results

High SGR was associated with higher T stage at resection, shorter doubling time, and elevated HbA1c (all P ≤ 0.01). Patients with high SGR had significantly decreased 5-year OS (63 vs 80%, P = 0.01) and disease-specific survival (72 vs 91%, P = 0.03) compared to those with low SGR. In patients with small (≤ 2 cm) tumors (N = 106), high SGR predicted lower 5-year OS (79 vs 96%, P = 0.01). On multivariate analysis, high SGR was independently associated with worse OS (hazard ratio 2.67, 95% confidence interval 1.05–6.84, P = 0.04).

Conclusion

High SGR is associated with worse survival in PNET patients. Evaluating PNET SGR may enhance clinical decision-making, particularly when weighing expectant management versus surgery in patients with small tumors.

Available only for authorised users

Halfdanarson TR, Rubin J, Farnell MB, Grant CS, Petersen GM. Pancreatic endocrine neoplasms: epidemiology and prognosis of pancreatic endocrine tumors. Endocr Relat Cancer. 2008;15(2):409–427. https://doi.org/10.1677/erc-07-0221.CrossRefPubMedPubMedCentral

Milan SA, Yeo CJ. Neuroendocrine tumors of the pancreas. Curr Opin Oncol. 2012;24(1):46–55. https://doi.org/10.1097/cco.0b013e32834c554d.CrossRefPubMed

Jiao Y, Shi C, Edil BH, et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science. 2011;331(6021):1199–1203. https://doi.org/10.1126/science.1200609.CrossRefPubMedPubMedCentral

Kulke MH, Anthony LB, Bushnell DL, et al. NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. Pancreas. 2010;39(6):735–752. https://doi.org/10.1097/mpa.0b013e3181ebb168.CrossRefPubMedPubMedCentral

Ellison TA, Wolfgang CL, Shi C, et al. A single institutionʼs 26-year experience with nonfunctional pancreatic neuroendocrine tumors: a validation of current staging systems and a new prognostic nomogram. Ann Surg. 2014;259(2):204–212. https://doi.org/10.1097/sla.0b013e31828f3174.CrossRefPubMedPubMedCentral

Kleeff J, Korc M, Apte M, et al. Pancreatic cancer. Nat Rev Dis Primers. 2016;2:1–23. https://doi.org/10.1038/nrdp.2016.22.CrossRef

Gao Y, Gao H, Wang G, et al. A meta-analysis of prognostic factor of pancreatic neuroendocrine neoplasms. Sci Rep. 2018;8(7271):1–8. https://doi.org/10.1038/s41598-018-24072-0.CrossRef

Kim S-J, Kim JW, Oh D-Y, et al. Clinical course of neuroendocrine tumors with different origins (the pancreas, gastrointestinal tract, and lung). Am J Clin Oncol. 2012;35(6):549–556. https://doi.org/10.1097/coc.0b013e31821dee0f.CrossRefPubMed

Cherenfant J, Stocker SJ, Gage MK, et al. Predicting aggressive behavior in nonfunctioning pancreatic neuroendocrine tumors. Surgery. 2013;154(4):785–793. https://doi.org/10.1016/j.surg.2013.07.004.CrossRefPubMed

10.

Bartsch DK, Slater EP, Albers M, et al. Higher risk of aggressive pancreatic neuroendocrine tumors in MEN1 patients with MEN1 mutations affecting the CHES1 interacting MENIN domain. J Clin Endocrinol Metab. 2014;99(11):E2387–E2391. https://doi.org/10.1210/jc.2013-4432.CrossRef

11.

Basturk O, Tang L, Hruban RH, et al. Poorly differentiated neuroendocrine carcinomas of the pancreas: a clinicopathologic analysis of 44 cases. Am J Surg Pathol. 2014;38(4):437–447. https://doi.org/10.1097/pas.0000000000000169.CrossRefPubMedPubMedCentral

12.

Touzios JG, Kiely JM, Pitt SC, et al. Neuroendocrine hepatic metastases: does aggressive management improve survival? Ann Surg. 2005;241(5):776–785. https://doi.org/10.1097/01.sla.0000161981.58631.ab.CrossRefPubMedPubMedCentral

13.

Birnbaum DJ, Turrini O, Vigano L, et al. Surgical management of advanced pancreatic neuroendocrine tumors: short-term and long-term results from an international multi-institutional study. Ann Surg Oncol. 2015;22(3):1000–1007. https://doi.org/10.1245/s10434-014-4016-8.CrossRefPubMed

14.

Schurr PG, Strate T, Rese K, et al. Aggressive surgery improves long-term survival in neuroendocrine pancreatic tumors. Ann Surg. 2007;245(2):273–281. https://doi.org/10.1097/01.sla.0000232556.24258.68.CrossRefPubMedPubMedCentral

15.

Sharpe SM, In H, Winchester DJ, Talamonti MS, Baker MS. Surgical resection provides an overall survival benefit for patients with small pancreatic neuroendocrine tumors. J Gastrointest Surg. 2015;19(1):117–123. https://doi.org/10.1007/s11605-014-2615-0.CrossRefPubMed

16.

Finkelstein P, Sharma R, Picado O, et al. Pancreatic neuroendocrine tumors (panNETs): analysis of overall survival of nonsurgical management versus surgical resection. J Gastrointest Surg. 2017;21:855–866. https://doi.org/10.1007/s11605-017-3365-6.CrossRefPubMed

17.

Guo J, Zhao J, Bi X, et al. Should surgery be conducted for small nonfunctioning pancreatic neuroendocrine tumors: a systematic review. Oncotarget. 2017;8(21):35368–35375.CrossRef

18.

Bar-Moshe Y, Mazeh H, Grozinsky-Glasberg S. Non-functioning pancreatic neuroendorcine tumors: surgery or observation? World J Gastrointest Endosc. 2017;9(4):153–161.CrossRef

19.

Falconi M, Eriksson B, Kaltsas G, et al. ENETS consensus guidelines update for the management of patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors. Neuroendocrinology. 2016;103(2):153–171. https://doi.org/10.1159/000443171.CrossRefPubMedPubMedCentral

20.

Kulke M, Shah M, Benson, AB, et al. 2015 Neuroendocrine tumors, Version 1.2015. J Natl Compr Cancer Netw. 13(1):78–108.CrossRef

21.

Schwartz M. A biomathematical approach to clinical tumor growth. Cancer. 1961;14(6):1272–1294.CrossRef

22.

Mehrara E, Forssell-Aronsson E, Ahlman H, Bernhardt P. Specific growth rate versus doubling time for quantitative characterization of tumor growth rate. Cancer Res. 2007;67(8):3970–3975. https://doi.org/10.1158/0008-5472.can-06-3822.CrossRefPubMed

23.

Atallah S, Cho B, Allibhai Z, et al. Impact of pretreatment tumor growth rate on outcome of early-stage lung cancer treated with stereotactic body radiation therapy. Int J Radiat Oncol. 2014;89(3):532–538. https://doi.org/10.1016/j.ijrobp.2014.03.003.CrossRef

24.

Usada K, Saito Y, Sagawa M, et al. Tumor doubling time and prognostic assessment of patients with primary lung cancer. Cancer. 1994;74(8):2239–2244.CrossRef

25.

Koizumi S, Kida M, Yamauchi H, et al. Clinical implications of doubling time of gastrointestinal submucosal tumors. World J Gastroenterol. 2016;22(45):10015-10. https://doi.org/10.3748/wjg.v22.i45.10015.CrossRef

26.

Furukawa H, Iwata R, Moriyama N. Growth rate of pancreatic adenocarcinoma: initial clinical experience. Pancreas. 2001;22(4):366-369.CrossRef

27.

Nishida K, Kaneko T, Yoneda M, et al. Doubling time of serum CA 19-9 in the clinical course of patients with pancreatic cancer and its significant association with prognosis. J Surg Oncol. 1999;71:140–146.CrossRef

28.

Okazaki N, Yoshino M, Yoshida T, et al. Evaluation of the prognosis for small hepatocellular carcinoma based on tumor volume doubling time. Cancer. 1989;63:2207–2210.CrossRef

29.

De Rose AM, Cucchetti A, Clemente G, et al. Prognostic significance of tumor doubling time in mass-forming type cholangiocarcinoma. J Gastrointest Surg. 2013;17(4):739–747. https://doi.org/10.1007/s11605-012-2129-6.CrossRefPubMed

30.

Zhang L, Yin W, Yao L, et al. Growth pattern of clear cell renal cell carcinoma in patients with delayed surgical intervention: fast growth rate correlates with high grade and may result in poor prognosis. BioMed Res Int. 2015;2015(4):1–8. https://doi.org/10.1155/2015/598134.CrossRef

31.

Nagore E, Martorell-Calatayud A. Growth rate as an independent prognostic factor in localized invasive cutaneous melanoma. J Eur Acad Dermatol Venereol. 2011;25(5):617–618. https://doi.org/10.1111/j.1468-3083.2011.03997.x.CrossRef

32.

Eskelin S, Pyrhonen S, Summanen P, Hahka-Kemppinen M, Kivela T. Tumor doubling times in metastatic malignant melanoma of the uvea: tumor progression before and after treatment. Opthalmology. 2000;107(8):1443–1449.CrossRef

33.

Dromain, C., et al. Tumor growth rate as a metric of progression, response, and prognosis in pancreatic and intestinal neuroendocrine tumors. BMC Cancer. 2019;19(1): 66.CrossRef

34.

Matkar S, Thiel A, Hua X. Menin: a scaffold protein that controls gene expression and cell signaling. Trends Biochem Sci. 2013;38(8):394–402. https://doi.org/10.1016/j.tibs.2013.05.005.CrossRefPubMedPubMedCentral

35.

Peeters K, Van Leemputte F, Fischer B, et al. Fructose-1,6-bisphosphate couples glycolytic flux to activation of Ras. Nat Commun. 2017;8(922):1–15. https://doi.org/10.1038/s41467-017-01019-z.CrossRef

36.

Garcia-Jimenez C, Garcia-Martinez JM, Chocarro-Calvo A, la Vieja De A. A new link between diabetes and cancer: enhanced WNT/β-catenin signalling by high glucose. J Mol Endocrinol. 2013;52(1):R51–R66.CrossRef

37.

Gallo M, Ruggeri RM, Muscogiuri G, et al. Diabetes and pancreatic neuroendocrine tumours: which interplays, if any? Cancer Treat Rev. 2018;67:1–9. https://doi.org/10.1016/j.ctrv.2018.04.013.CrossRefPubMed

38.

Hassan MM, Phan A, Li D, Dagohoy CG, Leary C, Yao JC 2008 Risk factors associated with neuroendocrine tumors: a U.S.-based case–control study. Int J Cancer. 123(4):867–873. https://doi.org/10.1002/ijc.23529.CrossRefPubMed

39.

Pannala R, Leirness JB, Bamlet WR, Basu A, Petersen GM, Chari ST. Prevalence and clinical profile of pancreatic cancer—associated diabetes mellitus. Gastroenterology. 2008;134(4):981–987. https://doi.org/10.1053/j.gastro.2008.01.039.CrossRefPubMedPubMedCentral

40.

Ben Q, Zhong J, Fei J, et al. Risk factors for sporadic pancreatic neuroendocrine tumors: a case–control study. Sci Rep. 2016;6(36073):1–9. https://doi.org/10.1038/srep36073.CrossRef

41.

Leoncini E, Carioli G, La Vecchia C, Boccia S, Rindi G. Risk factors for neuroendocrine neoplasms: a systematic review and meta-analysis. Ann Oncol. 2016;27(1):68–81. https://doi.org/10.1093/annonc/mdv505.CrossRefPubMed

42.

Kuo EJ, Salem RR. Population-level analysis of pancreatic neuroendocrine tumors 2 cm or less in size. Ann Surg Oncol. 2013;20(9):2815–2821. https://doi.org/10.1245/s10434-013-3005-7.CrossRefPubMed

Title: Specific Growth Rate as a Predictor of Survival in Pancreatic Neuroendocrine Tumors: A Multi-institutional Study from the United States Neuroendocrine Study Group
Authors: Jordan J. Baechle, BS
Paula Marincola Smith, MD
Marcus Tan, MD
Carmen C. Solórzano, MD
Alexandra G. Lopez-Aguiar, MD
Mary Dillhoff, MD
Eliza W. Beal, MD
George Poultsides, MD
Eleftherios Makris, MD
Flavio G. Rocha, MD
Angelena Crown, MD
Clifford Cho, MD
Megan Beems, MD
Emily R. Winslow, MD
Victoria R. Rendell, MD
Bradley A. Krasnick, MD
Ryan Fields, MD
Shishir K. Maithel, MD
Christina E. Bailey, MD
Kamran Idrees, MD
Publication date: 01-10-2020
Publisher: Springer International Publishing
Keyword: Neuroendocrine Tumor
Published in: Annals of Surgical Oncology / Issue 10/2020
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-020-08497-4

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Specific Growth Rate as a Predictor of Survival in Pancreatic Neuroendocrine Tumors: A Multi-institutional Study from the United States Neuroendocrine Study Group

Abstract

Background

Methods

Results

Conclusion

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 10/2020

Factors Predicting Breast Cancer Development in Women During Surveillance After Surgery for Atypical Ductal Hyperplasia of the Breast: Analysis of Clinical, Radiologic, and Histopathologic Features

Increased Rate of Complete Pathologic Response After Neoadjuvant FOLFIRINOX for BRCA Mutation Carriers with Borderline Resectable Pancreatic Cancer

Long-Term Outcomes of Pulmonary Metastasectomy for Uterine Malignancies: A Multi-institutional Study in the Current Era

ASO Author Reflections: Does Site Matter? Impact of Tumor Location on Pathologic Characteristics, Recurrence, and Survival of Resected Pancreatic Ductal Adenocarcinoma

Prognostic Value of the C-Reactive Protein/Lymphocyte Ratio in Pancreatic Cancer

ASO Author Reflections: C-Reactive Protein/Lymphocyte Ratio as a Promising Marker for Predicting Survival in Pancreatic Cancer